Brez internetne povezave — prikazana je shranjena različica strani.

Novartis AG ADR

USUSD
← Na Filter Delnic

Novartis AG ADR (SW:NOVN) — Drug Manufacturers - General. Število borz, na katerih se trgujejo delnice družbe: 7. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.

O Podjetju

Spletna Stran
novartis.com
Sektor
Healthcare · Drug Manufacturers - General
Sedež
BASEL, Switzerland
Izvršni Direktor
Vasant Narasimhan
Zaposleni
75 267
Ustanovljena
1996
Delnice v Obtoku
1.91 mrd. na dan 2025-12-31
Prosto Prenosljive Delnice
1.86 mrd.
Tržna Kapitalizacija
276.48 mrd. USD
Notranje Osebe
0.01%
Institucionalni Vlagatelji
7.27%
Panoga (SIC)
Pharmaceutical Preparations
Pravna Oblika
MVII
ISIN
CH0012005267
LEI
5493007HIVTX6SY6XD66
Delež Izplačila
56.0%
FCF
17.6 mrd. USD
44%
Dolg
29.4 mrd. USD
1.0 let FCF
Dividendni Staž
20 let
Dobički, FCF in izplačane dividende — za 12 mesecev do 31.12.2025 (najnovejše poročilo podjetja).
Opis

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Borze in Oznake

BorzaOznakaValutaCenaVrsta
US USA StocksNVSEF OTCUSD139.9825 +3.12%navadne delnice
LSE London Stock Exchange0QLR IOBCHF82.63 +0.00%navadne delnice
MI Borsa Italiana (Milan)1NOVN dodatnaEUR128.4 +0.28%navadne delnice
SW SIX Swiss ExchangeNOVN glavnaCHF119.8 -0.13%navadne delnice
SW SIX Swiss ExchangeNOVNEE dodatnaCHF120.02 -1.80%navadne delnice
VI Vienna Stock ExchangeNOVN dodatnaEUR127.32 -0.31%navadne delnice
XETRA XetraNOT dodatnaEUR126.82 +0.48%navadne delnice

Cena v 3 Mesecih

dan rasti dan padca ex-dividendni datum datum izplačilaPremaknite miško / tapnite dan — otvoritvena, zaključna, najvišja in najnižja cena

Dividende

Na leto, SW:NOVN: 3.7 CHF (1 izpl.)

Novartis AG ADR (NOVN) izplačuje dividende enkrat letno. Na leto (12 mesecev do in vključno z najnovejšim napovedanim plačilom): 3.7 CHF na delnico (plačila: 1). To je približno 3.09% trenutne cene delnice. Glede na zgodovino izplačil se naslednji datum ex-dividende pričakuje okoli 15.03.2027. Leta neprekinjenih dividend: 20.

Ex-DatumIzplačiloZnesek%VrstaOznaka
2026-03-102026-03-123.7000 CHF3.1/3.1 %letnoSW:NOVN
2025-03-112025-03-133.5000 CHF2.9/2.9 %letnoSW:NOVN
2024-03-07—3.3000 CHF2.8/2.8 %letnoSW:NOVN
2023-03-09—3.2000 CHF2.7/2.7 %letnoSW:NOVN
2022-03-08—3.1000 CHF2.6/2.6 %letnoSW:NOVN
oglas

Največji Imetniki

ImetnikDeležDelniceDatum Poročila
VANGUARD STAR FUNDS-Vang…1.35%27.43 mio.2026-07-31
VANGUARD TAX-MANAGED FUN…0.9%18.24 mio.2026-06-30
Fisher Asset Management,…0.76%15.52 mio.2026-06-30
iShares Trust-iShares Co…0.67%13.69 mio.2026-08-31
Goldman Sachs TRT II-Gol…0.6%12.19 mio.2026-07-31
Artisan Partners Funds I…0.51%10.29 mio.2026-06-30
Dodge & Cox Funds-Dodge…0.44%8.9 mio.2026-06-30
Morgan Stanley0.43%8.73 mio.2026-06-30
Dimensional Fund Advisor…0.4%8.12 mio.2026-06-30
Fidelity Concord Street…0.35%7.12 mio.2026-07-31
Primecap Management Comp…0.32%6.59 mio.2026-06-30
iShares Trust-iShares MS…0.32%6.53 mio.2026-08-31
LOOMIS SAYLES & CO L P0.26%5.24 mio.2026-06-30
MFS Series Trust XVII-MF…0.26%5.22 mio.2026-06-30
Bank of America Corporat…0.24%4.91 mio.2026-06-30
VANGUARD SPECIALIZED FUN…0.23%4.66 mio.2026-07-31
VANGUARD CHESTER FUNDS-V…0.21%4.25 mio.2026-06-30
Franklin Resources, Inc.0.16%3.25 mio.2026-06-30
Blackrock Inc.0.15%3.05 mio.2026-06-30
Goldman Sachs Group Inc0.15%2.98 mio.2026-06-30
Northern Trust Corporati…0.14%2.79 mio.2026-06-30
DFA INVESTMENT DIMENSION…0.11%2.14 mio.2026-04-30
LOOMIS SAYLES FUNDS II-L…0.07%1.42 mio.2026-06-30
VANGUARD HORIZON FUNDS-V…0.06%1.21 mio.2026-06-30
Franklin Mutual Series F…0.06%1.19 mio.2026-06-30
JANUS INVESTMENT FUND-Ja…0.05%949 7262026-06-30
Principal Funds, Inc-Equ…0.05%945 0912026-04-30
Dimensional ETF Trust-Di…0.04%888 8552026-04-30
Franklin Mutual Series F…0.04%812 6182026-06-30
Dimensional ETF Trust-Di…0.04%716 8362026-04-30
Pacer Advisors, Inc.0.02%482 1532026-06-30
Partners Capital Investm…0%24 3352026-06-30
Paradigm Asset Managemen…0%21 5142026-06-30
Generali Investments Cee…0%15 7292026-06-30